ArticleScientific data2026
BreastDCEDL: A standardized deep learning-ready breast DCE-MRI dataset of 2,070 patients.
Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Attention-Driven CNNs as a Strong Default for HER2 Prediction from DCE-MRI: A Comparison with Transformer Architectures.Bioengineering (Basel, Switzerland) · 2026Article
- BreastDCEDL: A standardized deep learning-ready breast DCE-MRI dataset of 2,070 patients.Scientific data · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) is essential for monitoring breast cancer treatment response, yet deep learning progress is limited by the lack of standardized, multi-center datasets. We present BreastDCEDL, a deep learning-ready dataset comprising pretreatment 3D DCE-MRI scans from 2,070 patients across three cohorts: I-SPY1 (n = 172), I-SPY2 (n = 982), and Duke (n = 916). Raw DICOM files were converted to standardized 3D NIfTI format, preserving signal integrity and spatial resolution. The dataset includes unified tumor annotations-binary masks for I-SPY cohorts and bounding boxes for Duke-and harmonized clinical metadata. Pathologic complete response (pCR) data are available for 1,452 patients (100% of I-SPY1/I-SPY2, 32.5% of Duke). Clinical biomarkers include HR status (64.1% positive) and HER2 status (22.2% positive) for over 99% of patients. Predefined train-validation-test splits (1,532/268/270) maintain balanced distributions. BreastDCEDL fills a critical gap in public imaging resources, supporting development of advanced models for pCR prediction and other breast cancer analyses. The dataset is designed for broad reuse and is accompanied by processing tools to support community-driven AI research in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.